文献速递神经肿瘤

内镜经鼻垂体腺瘤切除术后第1天出院的评估

Evaluation of early postoperative day 1 discharge after endoscopic endonasal pituitary adenoma resection.
PubMed 文献 · J Neurosurg · 2021-10-15

该单中心回顾性研究纳入2005年至2020年726例内镜经鼻垂体腺瘤切除患者,其中24.5%于术后第1天出院。术后第1天出院者术中脑脊液漏更少、并发症率更低、30天再入院无增加;多因素分析显示尿崩症和术中脑脊液漏与延长住院风险增加相关,手术年代与第1天出院相关。

要点

  • 内镜经鼻垂体腺瘤切除术后第1天出院安全可行,不增加30天再入院风险。
  • 尿崩症和术中脑脊液漏与术后第1天不能出院风险增加独立相关。
  • 随手术年代推移,术后第1天出院比例显著增加。

核心结论

  • 内镜经鼻垂体腺瘤切除术后第1天出院安全可行,且不增加30天再入院风险。
  • 多因素分析中手术年代与降低延长住院风险相关,尿崩症和术中脑脊液漏与增加延长住院风险相关。

研究设计与样本

  • 单中心三级学术中心2005年2月至2020年2月内镜经鼻垂体腺瘤切除术患者的回顾性病历回顾。
  • 共纳入726例患者,平均年龄55岁,52%为男性;术后第1天出院定义为术后24小时内出院。

主要发现

  • 178例(24.5%)于术后第1天出院。
  • 术后第1天出院者更常见垂体偶发瘤(p=0.001)、使用硬膜替代物和DuraSeal(p=0.0001)、术中脑脊液漏更少(p=0.02)、术后并发症率更低(p=0.006)。
  • 术后第1天出院者大腺瘤比例更高(96.1% vs 91.4%,p=0.03),功能性肿瘤比例更低(p=0.02)。
  • 术后第1天出院者尿崩症发生率更低(1.7% vs 9.8%,p=0.0001),术后皮质醇减低更低(21.8% vs 12.1%,p=0.01),术后激素使用更低(44.6% vs 59.7%,p=0.003)。
  • 术后第1天出院者在2005-2010、2011-2015、2016-2020各时间段显著增加(p=0.0001)。

关键数值与推荐

  • 多因素分析:尿崩症与术后第1天不能出院风险增加相关(OR 7.02,95%CI 2.01-24.57;p=0.002)。
  • 多因素分析:术中脑脊液漏与术后第1天不能出院风险增加相关(OR 2.02,95%CI 1.25-3.28;p=0.004)。
  • 多因素分析:手术年代与术后第1天出院相关(OR 0.46,95%CI 0.3-0.71;p=0.0001)。

临床怎么用

  • 对于无尿崩症和术中脑脊液漏等风险因素的患者,可考虑术后第1天出院。
  • 手术年代较晚与第1天出院可能性增加相关,提示经验积累可能促进早期出院。

局限性

  • 回顾性单中心设计可能限制结论的外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: While multiple studies have evaluated the length of stay after endonasal transsphenoidal surgery (ETS) for pituitary adenoma, the potential for early discharge on postoperative day 1 (POD 1) remains unclear. The authors compared patients discharged on POD 1 with patients discharged on POD > 1 to better characterize factors that facilitate early discharge after ETS. METHODS: A retrospective chart review was performed for patients undergoing ETS for pituitary adenoma at a single tertiary care academic center from February 2005 to February 2020. Discharge on POD 1 was defined as a discharge within 24 hours of surgery. RESULTS: A total of 726 patients (mean age 55 years, 52% male) were identified, of whom 178 (24.5%) patients were discharged on POD 1. These patients were more likely to have pituitary incidentaloma (p = 0.001), require dural substitutes and DuraSeal (p = 0.0001), have fewer intraoperative CSF leaks (p = 0.02), and have lower postoperative complication rates (p = 0.006) compared with patients discharged on POD > 1. POD 1 patients also showed higher rates of macroadenomas (96.1% vs 91.4%, p = 0.03) and lower rates of functional tumors (p = 0.02). POD > 1 patients were more likely to have readmission within 30 days (p = 0.002), readmission after 30 days (p = 0.0001), nasal synechiae on follow-up (p = 0.003), diabetes insipidus (DI; 1.7% vs 9.8%, p = 0.0001), postoperative hypocortisolism (21.8% vs 12.1%, p = 0.01), and postoperative steroid usage (44.6% vs 59.7%, p = 0.003). The number of patients discharged on POD 1 significantly increased during each subsequent time epoch: 2005-2010, 2011-2015, and 2016-2020 (p = 0.0001). On multivariate analysis, DI (OR 7.02, 95% CI 2.01-24.57; p = 0.002) and intraoperative leak (OR 2.02, 95% CI 1.25-3.28; p = 0.004) were associated with increased risk for POD > 1 discharge, while operation epoch (OR 0.46, 95% CI 0.3-0.71; p = 0.0001) was associated with POD 1 discharge. CONCLUSIONS: This study demonstrates that discharge on POD 1 after ETS for pituitary adenomas was safe and feasible and without increased risk of 30-day readmission. On multivariate analysis, surgical epoch was associated with decreased risk of prolonged length of stay, while factors associated with increased risk of prolonged length of stay included DI and intraoperative CSF leak. These findings may help in selecting patients who are deemed reasonable for safe, early discharge after pituitary adenoma resection.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Yu S, Taghvaei M, Collopy S, et al. Evaluation of early postoperative day 1 discharge after endoscopic endonasal pituitary adenoma resection. J Neurosurg. 2021. PMID: 34653980. doi:10.3171/2021.5.JNS2185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。